Innovation and Opportunities in Pediatric Therapeutic Development

Affiliations

¹ Office of Pediatric Therapeutics, Office of Clinical Policy and Programs, Office of the Commissioner, U.S. Food and Drug Administration.
² Pediatric Development, Science and Innovation, Pediatric Center of Excellence, Clinical Development & Analytics, Novartis Pharmaceuticals Corporation.

Susan McCune et al. Ther Innov Regul Sci. 2019 Sep.

. 2019 Sep;53(5):564-566.

doi: 10.1177/2168479019869754.

¹ Office of Pediatric Therapeutics, Office of Clinical Policy and Programs, Office of the Commissioner, U.S. Food and Drug Administration.
² Pediatric Development, Science and Innovation, Pediatric Center of Excellence, Clinical Development & Analytics, Novartis Pharmaceuticals Corporation.

No abstract available

References

1. Spielberg SP, Portman R. New horizons in pediatric drug development. Therapeutic Innovation & Regulatory Science. 2015;49(5):613–614. - PubMed
1. Gamalo-Siebers M, Hampson L, Kordy K, et al. Incorporating innovative techniques toward extrapolation and efficient pediatric drug development. Therapeutic Innovation & Regulatory Science. 2019. doi:10.1177/2168479019842541 - DOI - PubMed
1. Liu X, Ward RM. Pharmacometrics in pediatrics. Therapeutic Innovation & Regulatory Science. 2019. doi:10.1177/216847901 9851793 - DOI - PubMed
1. Job K, Gamalo-Siebers M, Ward RM. Pediatric age groups and approach to studies. Therapeutic Innovation & Regulatory Science. 2019. doi:10.1177/2168479019856572 - DOI - PubMed
1. Hirschfeld S, Zajicek A. What could the future of safety monitoring look like? Therapeutic Innovation & Regulatory Science. 2019. doi: 10.1177/2168479019854339. - DOI - PubMed